VMET Market Analysis

News & Sentiment

25 articles · sorted by date
Page 1 of 2 · 25 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio26.33Forward 34.25
EPS (TTM)$0.362123.0% YoY
Profit margin49.9%BASIC MATERIALS
Market cap$1.03BSmall cap

Valuation

Forward P/E
34.25
PEG ratio
P/B
2.64
P/S (TTM)
13.91
EV/EBITDA
17.59

Profitability & growth

ROE (TTM)
12.2%
Operating margin
58.0%
Revenue growth YoY
391.9%
Dividend yield
Beta
Last earnings
Aug 13, 2026 · Estimate $0.06 · Reported $0.04
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Versamet Royalties Corporation Common Stock

Company profile

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
733 SEYMOUR STREET, VANCOUVER, BC
Fiscal year end
December
Latest quarter
Jun 30, 2026
Market cap$1.03B
Shares outstanding$108.8M
52W high$15.00
52W low$8.48

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer